Developments in the scientific understanding of osteoporosis

Arthritis Research and Therapy

Volumn 11, Issue 3, 2009, Pages

  Lane, Nancy E ^a   Yao, Wei ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DENOSUMAB; DICKKOPF 1 PROTEIN; GLUCOCORTICOID; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PROTEIN ANTIBODY; SCLEROSTIN; SCLEROSTIN ANTIBODY; SECRETED FRIZZLED RELATED PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WNT PROTEIN;

BONE DEVELOPMENT; BONE DISEASE; BONE METABOLISM; BONE STRESS; CELL DIFFERENTIATION; CELL FUNCTION; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG MEGADOSE; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOPATHOLOGY; MECHANICAL STRESS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOPOROSIS; OSTEOPOROSIS PSEUDOGLIOMA SYNDROME; OSTEOSCLEROSIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANIMAL; MEDICAL RESEARCH; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; OSTEOPOROSIS; SIGNAL TRANSDUCTION;

EID: 65949087872     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2656     Document Type: Review

References (74)

1. Datta HK Ng WF Walker JA Tuck SP Varanasi SS The cell biology of bone metabolism J Clin Pathol 2008, 61:577-587. 10.1136/jcp.2007.048868 18441154
2. Sims NA Gooi JH Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption Semin Cell Dev Biol 2008, 19:444-451. 10.1016/j.semcdb.2008.07.016 18718546
3. Lips P Courpron P Meunier PJ Mean wall thickness of trabecular bone packets in the human iliac crest: Changes with age Calcif Tissue Res 1978, 26:13-17. 10.1007/BF02013227 737547
4. Gillespie MT Impact of cytokines and T lymphocytes upon osteoclast differentiation and function Arthritis Res Ther 2007, 9:103. 1906805 17381830 10.1186/ar2141
5. Horowitz MC Lorenzo JA B lymphocytes and the skeleton Ann N Y Acad Sci 2007, 1117:82-93. 10.1196/annals.1402.045 17872391
6. Elefteriou F Regulation of bone remodeling by the central and peripheral nervous system Arch Biochem Biophys 2008, 473:231-236. 2430105 18410742 10.1016/j.abb.2008.03.016
7. Shahnazari M Yao W Corr M Lane NE Targeting the Wnt signaling pathway to augment bone formation Curr Osteoporos Rep 2008, 6:142-148. 10.1007/ s11914-008-0025-5 19032924
8. Huang H He X Wnt/beta-catenin signaling: New (and old) players and new insights Curr Opin Cell Biol 2008, 20:119-125. 2390924 18339531 10.1016/ j.ceb.2008.01.009
9. Gordon MD Nusse R Wnt signaling: Multiple pathways, multiple receptors, and multiple transcription factors J Biol Chem 2006, 281:22429-22433. 10.1074/jbc.R600015200 16793760
10. Vlad A Rohrs S Klein-Hitpass L Muller O The first five years of the Wnt targetome Cell Signal 2008, 20:795-802. 10.1016/j.cellsig.2007.10.031 18160255
11. Yadav VK Ryu JH Suda N Tanaka KF Gingrich JA Schütz G Glorieux FH Chiang CY Zajac JD Insogna KL Mann JJ Hen R Ducy P Karsenty G Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum Cell 2008, 135:825-837. 10.1016/j.cell.2008.09.059 19041748
12. Gong Y Slee RB Fukai N Rawadi G Roman-Roman S Reginato AM Wang H Cundy T Glorieux FH Lev D Zacharin M Oexle K Marcelino J Suwairi W Heeger S Sabatakos G Apte S Adkins WN Allgrove J Arslan-Kirchner M Batch JA Beighton P Black GC Boles RG Boon LM Borrone C Brunner HG Carle GF Dallapiccola B De Paepe A et al LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development Cell 2001, 107:513-523. 10.1016/ S0092-8674(01)00571-2 11719191
13. Boyden LM Mao J Belsky J Mitzner L Farhi A Mitnick MA Wu D Insogna K Lifton RP High bone density due to a mutation in LDL-receptor-related protein 5 N Engl J Med 2002, 346:1513-1521. 10.1056/NEJMoa013444 12015390
14. Little RD Carulli JP Del Mastro RG Dupuis J Osborne M Folz C Manning SP Swain PM Zhao SC Eustace B Lappe MM Spitzer L Zweier S Braunschweiger K Benchekroun Y Hu X Adair R Chee L FitzGerald MG Tulig C Caruso A Tzellas N Bawa A Franklin B McGuire S Nogues X Gong G Allen KM Anisowicz A Morales AJ et al A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait Am J Hum Genet 2002, 70:11-19. 419982 11741193 10.1086/338450
15. Akhter MP Wells DJ Short SJ Cullen DM Johnson ML Haynatzki GR Babij P Allen KM Yaworsky PJ Bex F Recker RR Bone biomechanical properties in LRP5 mutant mice Bone 2004, 35:162-169. 10.1016/j.bone.2004.02.018 15207752
16. Babij P Zhao W Small C Kharode Y Yaworsky PJ Bouxsein ML Reddy PS Bodine PV Robinson JA Bhat B Marzolf J Moran RA Bex F High bone mass in mice expressing a mutant LRP5 gene J Bone Miner Res 2003, 18:960-974. 10.1359/ jbmr.2003.18.6.960 12817748
17. Ferrari SL Deutsch S Baudoin C Cohen-Solal M Ostertag A Antonarakis SE Rizzoli R de Vernejoul MC LRP5 gene polymorphisms and idiopathic osteoporosis in men Bone 2005, 37:770-775. 10.1016/j.bone.2005.06.017 16168727
18. Semenov MV He X LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST J Biol Chem 2006, 281:38276-38284. 10.1074/jbc.M609509200 17052975
19. Balemans W Ebeling M Patel N Van Hul E Olson P Dioszegi M Lacza C Wuyts W Ende Van Den J Willems P Paes-Alves AF Hill S Bueno M Ramos FJ Tacconi P Dikkers FG Stratakis C Lindpaintner K Vickery B Foernzler D Van Hul W Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) Hum Mol Genet 2001, 10:537-543. 10.1093/ hmg/10.5.537 11181578
20. Balemans W Foernzler D Parsons C Ebeling M Thompson A Reid DM Lindpaintner K Ralston SH Van Hul W Lack of association between the SOST gene and bone mineral density in perimenopausal women: Analysis of five polymorphisms Bone 2002, 31:515-519. 10.1016/S8756-3282(02)00844-X 12398949
21. Balemans W Patel N Ebeling M Van Hul E Wuyts W Lacza C Dioszegi M Dikkers FG Hildering P Willems PJ Verheij JB Lindpaintner K Vickery B Foernzler D Van Hul W Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease J Med Genet 2002, 39:91-97. 1735035 11836356 10.1136/jmg.39.2.91
22. Brunkow ME Gardner JC Van Ness J Paeper BW Kovacevich BR Proll S Skonier JE Zhao L Sabo PJ Fu Y Alisch RS Gillett L Colbert T Tacconi P Galas D Hamersma H Beighton P Mulligan J Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein Am J Hum Genet 2001, 68:577-589. 1274471 11179006 10.1086/318811
23. Li J Sarosi I Cattley RC Pretorius J Asuncion F Grisanti M Morony S Adamu S Geng Z Qiu W Kostenuik P Lacey DL Simonet WS Bolon B Qian X Shalhoub V Ominsky MS Zhu Ke H Li X Richards WG Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia Bone 2006, 39:754-766. 10.1016/j.bone.2006.03.017 16730481
24. Morvan F Boulukos K Clément-Lacroix P Roman Roman S Suc-Royer I Vayssière B Ammann P Martin P Pinho S Pognonec P Mollat P Niehrs C Baron R Rawadi G Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass J Bone Miner Res 2006, 21:934-945. 10.1359/jbmr.060311 16753024
25. Yaccoby S Ling W Zhan F Walker R Barlogie B Shaughnessy JD Jr Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo Blood 2007, 109:2106-2111. 1801040 17068150 10.1182/blood-2006-09-047712
26. Qiang YW Chen Y Stephens O Brown N Chen B Epstein J Barlogie B Shaughnessy JD Jr Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: A potential mechanism underlying osteolytic bone lesions in multiple myeloma Blood 2008, 112:196-207. 10.1182/blood-2008-01-132134 18305214
27. Hall CL Keller ET The role of Wnts in bone metastases Cancer Metastasis Rev 2006, 25:551-558. 10.1007/s10555-006-9022-2 17160558
28. Voorzanger-Rousselot N Goehrig D Journe F Doriath V Body JJ Clezardin P Garnero P Increased Dickkopf-1 expression in breast cancer bone metastases Br J Cancer 2007, 97:964-970. 17876334
29. Hurson CJ Butler JS Keating DT Murray DW Sadlier DM O'Byrne JM Doran PP Gene expression analysis in human osteoblasts exposed to dexamethasone identifies altered developmental pathways as putative drivers of osteoporosis BMC Musculoskelet Disord 2007, 8:12. 1803771 17295923 10.1186/1471-2474-8-12
30. Yao W Cheng Z Busse C Pham A Nakamura MC Lane NE Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: A longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice Arthritis Rheum 2008, 58:1674-1686. 10.1002/art.23454 18512788
31. Yao W Cheng Z Busse C Pham A Lane N Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates PTH bone anabolic effects [abstract] J Bone Miner Res 2008, 23(suppl 1):S29.
32. Blair H Sun L Kohanski RA Balanced regulation of proliferation, growth, differentiation, and degradation in skeletal cells Ann N Y Acad Sci 2007, 1116:165-173. 10.1196/annals.1402.029 17646258
33. Takada I Suzawa M Matsumoto K Kato S Suppression of PPAR-γ transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts Ann N Y Acad Sci 2007, 1116:182-195. 10.1196/ annals.1402.034 17656564
34. Almeida M Han L Bellido T Manolagas SC Kousteni S Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by beta-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT J Biol Chem 2005, 280:41342-41351. 10.1074/jbc.M502168200 16251184
35. Baron R Rawadi G Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton Endocrinology 2007, 148:2635-2643. 10.1210/en.2007-0270 17395698
36. Baron R Rawadi G Roman-Roman S Wnt signaling: A key regulator of bone mass Curr Top Dev Biol 2006, 76:103-127. 10.1016/S0070-2153(06)76004-5 17118265
37. Holmen SL Giambernardi TA Zylstra CR Buckner-Berghuis BD Resau JH Hess JF Glatt V Bouxsein ML Ai M Warman ML Williams BO Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6 J Bone Miner Res 2004, 19:2033-2040. 10.1359/JBMR.040907 15537447
38. Cheon SS Cheah AY Turley S Nadesan P Poon R Clevers H Alman BA beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds Proc Natl Acad Sci USA 2002, 99:6973-6978. 124513 11983872 10.1073/pnas.102657399
39. Williams LJ Henry MJ Berk M Dodd S Jacka FN Kotowicz MA Nicholson GC Pasco JA Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression Int Clin Psychopharmacol 2008, 23:84-87. 10.1097/YIC.0b013e3282f2b3bb 18301122
40. Haney EM Chan BK Diem SJ Ensrud KE Cauley JA Barrett-Connor E Orwoll E Bliziotes MM Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men Arch Intern Med 2007, 167:1246-1251. 10.1001/archinte.167.12.1246 17592097
41. Noble BS The osteocyte lineage Arch Biochem Biophys 2008, 473:106-111. 10.1016/j.abb.2008.04.009 18424256
42. Laughlin SB de Ruyter van Steveninck RR Anderson JC The metabolic cost of neural information Nat Neurosci 1998, 1:36-41. 10.1038/236 10195106
43. Keller H Kneissel M SOST is a target gene for PTH in bone Bone 2005, 37:148-158. 10.1016/j.bone.2005.03.018 15946907
44. Belanger LF Narbaitz R The; mecanism of cementing line formation in the bones of cestrum-fed chicks Rev Can Biol 1978, 37:5-14. 209501
45. Drueke T Bordier PJ Man NK Jungers P Marie P Effects of high dialysate calcium concentration on bone remodelling, serum biochemistry, and parathyroid hormone in patients with renal osteodystrophy Kidney Int 1977, 11:267-274. 10.1038/ki.1977.40 857076
46. Wright PH Jowsey JO Robb RA Osteocyte lacunar area in normal bone, hyperparathyroidism, renal disease, and osteoporosis Surg Forum 1978, 29:558-559. 401260
47. Belanger LF Osteocytic osteolysis Calcif Tissue Res 1969, 4:1-12. 10.1007/BF02279101 4310125
48. Lane NE Yao W Balooch M Nalla RK Balooch G Habelitz S Kinney JH Bonewald LF Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice J Bone Miner Res 2006, 21:466-476. 1797152 16491295 10.1359/JBMR.051103
49. Yao W Cheng Z Pham A Busse C Zimmermann EA Ritchie RO Lane NE Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization Arthritis Rheum 2008, 58:3485-3497. 10.1002/ art.23954 18975341
50. Teti A Zallone A Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited Bone 2009, 44:11-16. 10.1016/ j.bone.2008.09.017 18977320
51. Noble BS Peet N Stevens HY Brabbs A Mosley JR Reilly GC Reeve J Skerry TM Lanyon LE Mechanical loading: Biphasic osteocyte survival and targeting of osteoclasts for bone destruction in rat cortical bone Am J Physiol Cell Physiol 2003, 284:C934-C943. 12477665
52. Balemans W Piters E Cleiren E Ai M Van Wesenbeeck L Warman ML Van Hul W The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations Calcif Tissue Int 2008, 82:445-453. 10.1007/s00223-008-9130-9 18521528
53. Bellido T Downregulation of SOST/sclerostin by PTH: A novel mechanism of hormonal control of bone formation mediated by osteocytes J Musculoskelet Neuronal Interact 2006, 6:358-359. 17185824
54. Li X Ominsky MS Niu QT Sun N Daugherty B D'Agostin D Kurahara C Gao Y Cao J Gong J Asuncion F Barrero M Warmington K Dwyer D Stolina M Morony S Sarosi I Kostenuik PJ Lacey DL Simonet WS Ke HZ Paszty C Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength J Bone Miner Res 2008, 23:860-869. 10.1359/ jbmr.080216 18269310
55. Li X Ominsky MS Warmington KS Morony S Gong J Cao J Gao Y Shalhoub V Tipton B Haldankar R Chen Q Winters A Boone T Geng Z Niu QT Ke HZ Kostenuik PJ Simonet WS Lacey DL Paszty C Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis J Bone Miner Res 2009, 24:578-588. 10.1359/ jbmr.081206 19049336
56. Padhi D Stouch B Jang G Fang L Darling M Glise H Robinson M Harris S Posvar E Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women [abstract] J Bone Miner Res 2007, 22(suppl 1):S37.
57. Lacey DL Timms E Tan HL Kelley MJ Dunstan CR Burgess T Elliott R Colombero A Elliott G Scully S Hsu H Sullivan J Hawkins N Davy E Capparelli C Eli A Qian YX Kaufman S Sarosi I Shalhoub V Senaldi G Guo J Delaney J Boyle WJ Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 1998, 93:165-176. 10.1016/ S0092-8674(00)81569-X 9568710
58. Yasuda H Shima N Nakagawa N Yamaguchi K Kinosaki M Mochizuki S Tomoyasu A Yano K Goto M Murakami A Tsuda E Morinaga T Higashio K Udagawa N Takahashi N Suda T Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 1998, 95:3597-3602. 19881 9520411 10.1073/pnas.95.7.3597
59. Gallagher JC Advances in bone biology and new treatments for bone loss Maturitas 2008, 60:65-69. 10.1016/j.maturitas.2008.04.005 18555623
60. Simonet WS Lacey DL Dunstan CR Kelley M Chang MS Lüthy R Nguyen HQ Wooden S Bennett L Boone T Shimamoto G DeRose M Elliott R Colombero A Tan HL Trail G Sullivan J Davy E Bucay N Renshaw-Gegg L Hughes TM Hill D Pattison W Campbell P Sander S Van G Tarpley J Derby P Lee R Boyle WJ Osteoprotegerin: A novel secreted protein involved in the regulation of bone density Cell 1997, 89:309-319. 10.1016/S0092-8674(00)80209-3 9108485
61. Bucay N Sarosi I Dunstan CR Morony S Tarpley J Capparelli C Scully S Tan HL Xu W Lacey DL Boyle WJ Simonet WS osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 1998, 12:1260-1268. 316769 9573043 10.1101/gad.12.9.1260
62. Kong YY Yoshida H Sarosi I Tan HL Timms E Capparelli C Morony S Oliveirados-Santos AJ Van G Itie A Khoo W Wakeham A Dunstan CR Lacey DL Mak TW Boyle WJ Penninger JM OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 1999, 397:315-323. 10.1038/16852 9950424
63. Bekker PJ Holloway DL Rasmussen AS Murphy R Martin SW Leese PT Holmes GB Dunstan CR DePaoli AM A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 2004, 19:1059-1066. 10.1359/JBMR.040305 15176987
64. McClung MR Lewiecki EM Cohen SB Bolognese MA Woodson GC Moffett AH Peacock M Miller PD Lederman SN Chesnut CH Lain D Kivitz AJ Holloway DL Zhang C Peterson MC Bekker PJ AMG 162 Bone Loss Study Group Denosumab in postmenopausal women with low bone mineral density N Engl J Med 2006, 354:821-831. 10.1056/NEJMoa044459 16495394
65. Cohen SB Dore RK Lane NE Ory PA Peterfy CG Sharp JT Heijde van der D Zhou L Tsuji W Newmark R Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multi-center, randomized, double-blind, placebo-controlled, phase II clinical trial Arthritis Rheum 2008, 58:1299-1309. 10.1002/art.23417 18438830
66. Lane NE Sanchez S Modin GW Genant HK Pierini E Arnaud CD Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial J Clin Invest 1998, 102:1627-1633. 509014 9788977 10.1172/JCI3914
67. Buxton EC Yao W Lane NE Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34) J Clin Endocrinol Metab 2004, 89:3332-3336. 10.1210/jc.2003-032066 15240611
68. Hurley; M Yao W Lane NE Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34) Osteoporos Int 2005, 16:2080-2084. 10.1007/ s00198-005-1998-x 16133640
69. Black DM Greenspan SL Ensrud KE Palermo L McGowan JA Lang TF Garnero P Bouxsein ML Bilezikian JP Rosen CJ The effects of parathyroid hormone and alendronate alone or in combination in postmeopausal osteoporosis N Engl J Med 2003, 349:1207-1215. 10.1056/NEJMoa031975 14500804
70. Finkelstein JS Hayes A Hunzelman JL Wyland JJ Lee H Neer RM The effects of parathyroid hormone, alendronate, or both in men with osteoporosis N Engl J Med 2003, 349:1216-1226. 10.1056/NEJMoa035725 14500805
71. Diarra D Stolina M Polzer K Zwerina J Ominsky MS Dwyer D Korb A Smolen J Hoffmann M Scheinecker C Heide van der D Landewe R Lacey D Richards WG Schett G Dickkopf-1 is a master regulator of joint remodeling Nat Med 2007, 13:156-163. 10.1038/nm1538 17237793
72. Keffer J Probert L Cazlaris H Georgopoulos S Kaslaris E Kioussis D Kollias G Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis EMBO J 1991, 10:4025-4031. 453150 1721867
73. Goldring SR Goldring MB Eating bone or adding it: The Wnt pathway decides Nat Med 2007, 13:133-134. 10.1038/nm0207-133 17290270
74. Corr M Wnt-beta-catenin signaling in the pathogenesis of osteoarthritis Nat Clin Pract Rheumatol 2008, 4:550-556. 10.1038/ncprheum0904 18820702